삼성서울병원

Ko En

Hematology-Oncology Park, Young Suk M.D

Expertise
Colorectal Cancer
Treament Schedule 05 月
DATE
WEB
01
THU
02
FRI
03
SAT
04
SUN
05
MON
06
TUE
07
WEB
08
THU
09
FRI
10
SAT
11
SUN
12
MON
13
TUE
14
WEB
15
THU
16
FRI
17
SAT
18
SUN
19
MON
20
TUE
21
WEB
22
THU
23
FRI
24
SAT
25
SUN
26
MON
27
TUE
28
WEB
29
THU
30
FRI
31
AM
PM
Treament Schedule 06 月
DATE
SAT
01
SUN
02
MON
03
TUE
04
WEB
05
THU
06
FRI
07
SAT
08
SUN
09
MON
10
TUE
11
WEB
12
THU
13
FRI
14
SAT
15
SUN
16
MON
17
TUE
18
WEB
19
THU
20
FRI
21
SAT
22
SUN
23
MON
24
TUE
25
WEB
26
THU
27
FRI
28
SAT
29
SUN
30
AM
PM

Medical Education

1998~1999 Ph.D. in Medicine Graduate School, Korea University College of Medicine, Seoul, Korea
1982~1986 M.D. Seoul National University College of Medicine, Seoul, Korea

Post-Graduate Training

Fellowship   1990~1991 Hematology and Medical Oncology, Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
Residency   1987~1990 Seoul National University Hospital, Seoul, Korea
Internship   Seoul National University Hospital

Professional Appointments

2004~2010 Chief Clinical Trial Training Center Clinical Trial Center, Samsung Medical Center, Seoul, Korea
2000~2003 Chief Center for Clinical Trials, National Cancer Center Hospital, Kyonggi, Korea
1999~2000 Associate Professor Department of Internal Medicine, Halllym University College of Medicine
1996~1997 Consultant University of Pittsburgh National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, USA
1993 Clinical Fellow Fred Hutchinson Cancer Research Center, Seattle, USA

Professional Memberships

Member Korean Society of Medical Oncology
Member Korean Cancer Association
Member American Society of Clinical Oncology

Selected Publications

  • INVEST NEW DRUG 2021 10.1007/s10637-021-01110-9 A phase 1 dose-escalation and dose-expansion study to assess the safety and efficacy of CKD-516, a novel vascular disrupting agent, in combination with Irinotecan in patients with previously treated metastatic colorectal cancer Jeong1, H; Hong, YS; Kim, JE; Lim, HS; Ahn, JB; Shin, SJ; Park, YS; Kim, ST; Han, SW; Kim, TY; Kim, TW
    View PubMed
  • ANN ONCOL 2021 10.1016/j.annonc.2020.11.017 A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial Park1, SH; Lim, DH; Sohn, TS; Lee, J; Zang, DY; Kim, ST; Kang, JH; Oh, SY; Hwang, IG; Ji, JH; Shin, DB; Yu, JI; Kim, KM; An, JY; Choi, MG; Lee, JH; Kim, S; Hong, JY; Park, JO; Park, YS; Lim, HY; Bae, JM; Kang, WK
    View PubMed
  • ONCOLOGY-BASEL 2021 10.1159/000514404 Programmed Death Ligand 1 Expression as a Prognostic Marker in Patients with Advanced Biliary Tract Cancer Kim1, H; Kim, J; Byeon, S; Jang, KT; Hong, JY; Lee, JY; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST
    View PubMed
  • ONCOLOGIST 2021 10.1002/onco.13735 Proton Pump Inhibitor Use and the Efficacy of Chemotherapy in Metastatic Colorectal Cancer: A Post Hoc Analysis of a Randomized Phase III Trial (AXEPT) Kim1, SY; Lee, JS; Kang, J; Morita, S; Park, YS; Sakamoto, J; Muro, K; Xu, RH; Kim, TW
    View PubMed
  • THER ADV MED ONCOL 2021 10.1177/1758835921992992 Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors Kim1, H; Hong, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, KM; Kim, ST
    View PubMed